Potentiating effect of glabridin from Glycyrrhiza glabra on GABAA receptors  by Hoffmann, Katrin M. et al.
Biochemistry and Biophysics Reports 6 (2016) 197–202Contents lists available at ScienceDirectBiochemistry and Biophysics Reportshttp://d
2405-58
n Corr
Univers
E-mjournal homepage: www.elsevier.com/locate/bbrepPotentiating effect of glabridin from Glycyrrhiza glabra on GABAA
receptors
Katrin M. Hoffmann, Leopoldo Beltrán, Paul M. Ziemba, Hanns Hatt, Günter Gisselmann n
Ruhr-University Bochum, Department of Cell Physiology, Bochum, Germanya r t i c l e i n f o
Article history:
Received 22 December 2015
Received in revised form
7 April 2016
Accepted 14 April 2016
Available online 16 April 2016
Keywords:
GABAA Receptor
Glabridin
Insomnia
Anxiety
Xenopus Oocytes
Glycyrrhiza glabrax.doi.org/10.1016/j.bbrep.2016.04.007
08/& 2016 The Authors. Published by Elsevier
espondence to: Ruhr-University Bochum,
itätsstr. 150, 44780 Bochum, Germany.
ail address: guenter.gisselmann@rub.de (G. Gia b s t r a c t
Extracts from Glycyrrhiza are traditionally used for the treatment of insomnia and anxiety. Glabridin is
one of the main ﬂavonoid compounds from Glycyrrhiza glabra and displays a broad range of biological
properties. In the present work, we investigated the effect of glabridin on GABAA receptors. For this
purpose, we employed the two-electrode voltage-clamp technique on Xenopus laevis oocytes expressing
recombinant GABAA receptors. Through this approach, we observed that glabridin presents a strong
potentiating effect on GABAA α1β(13)γ2 receptors. The potentiation was slightly dependent on the β
subunit and was most pronounced at the α1β2γ2 subunit combination, which forms the most abundant
GABAA receptor in the CNS. Glabridin potentiated with an EC50 of 6.371.7 mM and decreased the EC50 of
the receptor for GABA by approximately 12-fold. The potentiating effect of glabridin is ﬂumazenil-in-
sensitive and does not require the benzodiazepine binding site. Glabridin acts on the β subunit of GABAA
receptors by a mechanism involving the M286 residue, which is a key amino acid at the binding site for
general anesthetics, such as propofol and etomidate. Our results demonstrate that GABAA receptors are
strongly potentiated by one of the main ﬂavonoid compounds from Glycyrrhiza glabra and suggest that
glabridin could contribute to the reported hypnotic effect of Glycyrrhiza extracts.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
GABAA receptors are chloride-selective, heteropentameric io-
notropic receptors that mediate fast inhibitory synaptic trans-
mission in the central nervous system. They constitute a target for
the majority of clinically relevant anesthetics, e.g., propofol and
etomidate [1]. They are also targets for many neuroleptic, anxio-
lytic and anticonvulsant drugs [2,3]. GABAA receptors are com-
posed of different combinations of the following subunits: α1–6,
β1–3, γ1–3, δ, ε, π and ϑ [2]. The most prominent native receptors
in the CNS are the post-synaptically localized heteromultimers of
α, β, and γ subunits. The GABA-binding pocket is formed by the α/
β-subunit interface, whereas the benzodiazepine-binding pocket
is located at the α/γ interface.
More than ten distinct modulatory binding sites in GABAA re-
ceptors are currently known, and these constitute the target of
many sedative, anticonvulsive, anxiolytic, antiepileptic, and hyp-
notic compounds of different chemical classes [4]. Benzodiaze-
pine-site agonists act mainly on γ2-containing GABAA receptors. InB.V. This is an open access article u
Department of Cellysiology,
sselmann).contrast, several other modulators, such as the general anesthetics
propofol or etomidate, target the β subunit [5]. Flavonoid mod-
ulation of GABAA receptors has been the focus of intense research
for many years. The mechanism of potentiation is complex, only
partially understood, and includes ﬂumazenil-sensitive modula-
tion at the benzodiazepine binding site, ﬂumazenil-insensitive
modulation at other sites and second-order modulation of ben-
zodiazepine potentiation [6].
Glabridin is a polyphenolic ﬂavonoid compound from liquorice
(Glycyrrhiza glabra, Fabaceae) and is one of the main components
of the ﬂavonoid fraction. It has a wide range of biological prop-
erties, ranging from neuroprotective to skin-whitening (reviewed
by [7]), and is used in dietary supplements, foods and cosmetic
products. Liquorice extracts show hypnotic-sedative actions in
animal models and are traditionally used for the treatment of in-
somnia and anxiety [7–9]. Prior research showed that low mM
concentrations of glabridin strongly potentiate GABA-induced
currents in rat dorsal raphe neurons [10]. However, until recently,
no data regarding the effect of glabridin on recombinant GABAA
receptors has been published, and the mechanism of potentiation
has not yet been studied. In the present work, we addressed these
questions and studied the effect of glabridin on different subtypes
of heterologously expressed GABAA receptors.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Modulating effect of glabridin on recombinant GABAA receptors. (a) Several components (10 mM) were screened for the potentiation of GABA-induced currents (left,
n¼3–4). The chemical structure of glabridin (right). (b) Representative voltage-clamp recording of a Xenopus oocyte expressing the α1β2γ2 GABAA subtype exposed to 3 mM
GABA in the absence and presence of glabridin 30 mM (left). Higher concentrations of glabridin leads to an activation of the GABAA receptor. (c) Dose-response relationship
for the effect of glabridin on GABA induced currents (n of 4–6 oocytes). (d) Co-application of glabridin (30 mM) leads to a leftward shift in the dose-response curve of GABA on
α1β2γ2 receptors (n of 4 oocytes). Higher concentrations of glabridin lead to an activation of the GABAA receptor (n of 4 oocytes). (e) Representative voltage-clamp recording
of a Xenopus oocyte exposed to increasing concentrations of GABA in the absence (left) and presence (right) of 30 mM glabridin.
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Table 1
Modulation of GABAA receptors subtypes by glabridin.
Subunit combination Modulatory EC50 (mM) GABA ECX (3 mM)a Fold potentiation by 30 mM glabridin Direct activation by 30 mM glabridin P-value
α1β2γ2 6.3071.70 11.6 6.2071.41 0.0770.02 P¼0.007
α1β2 9.6370.70 32.9 4.2370.56 0.1170.05 P¼0.003
α1β1γ2 17.2372.64 47.3 5.0771.45 0.1470.08 P¼0.005
α1β3γ2 6.8373.07 35.4 2.6370.42 0.0870.04 P¼0.016
α1β2(M286W)γ2 no potentiation 11.9 1.0470.05 0 ns
α1β2(N265M)γ2 32.6571.52 2.8 1.470.34 0 ns
a (10 mM for the α1β3γ2 combination, 1 mM for the α1β1γ2 combination).
Table 2
Modulation of GABAA receptors subtypes dose response relationship by glabridin.
Subunit combination GABA EC50 (mM) GABA EC50 (mM) with 30 mM glabridin Fold decrease P-value
α1β2γ2 20.5470.73 1.6770.12 12.3 Po0.0001
α1β2 5.5670.26 3.1370.37 1.8 ns
α1β1γ2 2.5170.24 0.5770.06 4.4 Po0.0001
α1β3γ2 4.6870.72 0.6970.12 6.8 Po0.0001
α1β2(M286W)γ2 13.3872.52 17.7875.57 0.75 ns
α1β2(N265M)γ2 141.97737.50 40.5774.29 3.5 P¼0.0096
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2.1. Expression system
Cloned cDNA for rat α1, β1 and β2, human β3 and murine γ2 in
psGEM [11] was linearized with PacI and used as templates for in
vitro transcription. cRNAs were prepared using the AmpliCap T7
high-yield message marker kit (Epicenter, Madison, WI), following
the manufacturer’s protocol. Oocytes were obtained as previously
described [12] and injected with a total amount of 7–20 ng of re-
ceptor coding cRNA using an injection-setup from WPI (Nanoliter
2000, Micro4). Injected oocytes were stored in ND 96 (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.2,
200 U/ml Penicillin, 200 μg/ml Streptomycin) at 14 °C. Measure-
ments were performed two to three days after cRNA-injection.
2.2. Electrophysiology
Electrophysiological recordings were performed using the two-
electrode voltage clamp technique as previously described [12]. All
measurements were performed in normal frog ringer (NFR)
(115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, 10 mM HEPES, pH 7.2).
Currents were recorded at a typical holding potential 40 mV
using the software Cell Works 6.1.1. (NPI).
2.3. Data analysis
The currents evoked by test substances or modulated GABA
currents were normalized to the induced currents of standard
GABA concentrations. Concentration response data were ﬁtted
with the Hill equation using SigmaPlot 8.0. Deviations are re-
presented by the standard error of the mean (SEM). Data sets were
tested for statistically signiﬁcant differences using Student's t-test
from Excel 2010 (Microsoft).3. Results
We screened different compounds present in liquorice (Gly-
cyrrhiza glabra, Fabaceae) for their modulatory action on GABAA
receptors using Xenopus laevis oocytes recombinantly expressingα1β2γ2 GABAA receptors and identiﬁed glabridin as one of the
active constituents (Fig. 1a, Supplementary Fig. 1). For the detailed
pharmacological characterization of glabridin's action of GABAA
receptors, we recombinantly expressed various GABAA receptor
subunit combinations and measured them by the two-electrode
voltage-clamp technique. By this approach, we found that glabri-
din (Fig. 1a) is a strong positive modulator (Fig. 1b) of re-
combinantly expressed α1β2γ2 GABAA receptors. As a next step,
we investigated this potentiating effect on the current evoked by
3 mM GABA (app. EC10–20) as a result of increasing concentrations
of glabridin. We observed that starting at concentrations of 1 mM,
there is potentiation of GABA-induced currents, with maximal
potentiation achieved at approximately 30 mM (Fig. 1c) and an EC50
of glabridin of 6.3071.70 mM. We then evaluated the effect of
glabridin at this saturating concentration on the dose-response
relationship of GABA on α1β2γ2 receptors (Fig. 1d and e). Glab-
ridin led to a strong increase in GABA's potency, as depicted by a
leftward shift in the dose-response relationship of GABA on
α1β2γ2 GABAA receptors; however, the maximally induced cur-
rent evoked by 1 mM GABA was not signiﬁcantly altered
(p¼0.055, n¼4). The EC50 for GABA changed from 20.570.8 mM in
the absence of glabridin to 1.770.2 mM in the presence of 30 mM
glabridin (Table 1 and 2). In the absence of GABA, lower con-
centrations of glabridin up to 10 mM failed to activate α1β2γ2
GABAA receptors; however, starting with a threshold concentra-
tion of 30 mM, elevated concentrations of 100 mM evoked up to
1777% (n¼4) of the maximally evoked current by saturating
GABA concentrations (Fig. 1b, d, Table 1).
Glabridin is an isoﬂavonoid. Because other ﬂavonoids have
been reported to bind to the benzodiazepine binding site located
at the α/γ interface of GABAA receptors, we examined whether
glabridin would still present a similar potentiating effect on GABAA
receptors lacking the γ subunit. For this, we used a combination of
α and β subunits to build a functional α1β2 GABAA receptor. On
this receptor type, we observed a signiﬁcant potentiating effect by
glabridin, which presented an EC50 value of 9.6370.70 mM
(Fig. 2a, Table 1). Elevated concentrations of glabridin (30 mM) led
to a small direct activation of the receptor (Table 1). Glabridin at a
concentration of 30 mM induced a shift in the EC50 for GABA from
5.5670.26 mM to 3.1370.37 mM, which is a smaller effect com-
pared to that on the receptor containing the γ2 subunit (Fig. 2a, b
Fig. 2. Modulation of different recombinant GABAA receptor isoforms by glabridin. (a) Dose-response relationship for the effect of glabridin on GABA induced currents of
receptors composed of α1β2, α1β1γ2, α1β3γ2 subunits (n of 4 oocytes). Co-application of glabridin (30 mM) with various concentration of GABA leads to a leftward shift in the
dose-response curve of GABA of (b) α1β2 (n of 6 oocytes), (c) α1β1γ2 (n of 4 oocytes) or (d) α1β3γ2 receptors (n of 4 oocytes).
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To investigate whether the modulatory effect of glabridin is
dependent on the β subunit, we evaluated the effect of this
compound on different combinations of GABAA receptors con-
taining different β subunits. Using Xenopus oocytes expressing
heteromeric α1β1γ2-and α1β3γ2 GABAA receptors, we observed a
strong potentiating effect on the GABA-induced currents (Fig. 2a,
Table 1). In both cases, the effect was similar to the potentiation
observed on the α1β2γ2 subtype. For these two subtypes, glabri-
din (30 mM) led to a leftward shift on the dose-response curve to
GABA (Table 2). For α1β1γ2, the EC50 shifted from 2.5170.24 to
0.5770.06 mM (Fig. 2c), while the α1β3γ2 subtype presented a
shift from 4.6870.72 to 0.6970.12 mM (Fig. 2d). In addition, for
these two subunit combinations, elevated concentrations of glab-
ridin (30 mM) led to a small direct activation of the receptor
(Table 1).
Our results indicate that the γ subunit is not required for the
potentiating effect of glabridin, but enhances the potentiating ef-
fect on the GABAA receptor. This subunit is known to be involved
in the interaction with well-known GABA-modulators, such as
benzodiazepines and ﬂavonoids [6]. We tested whether the ben-
zodiazepine antagonist ﬂumazenil could reduce glabridin po-
tentiation, which would be an indication of the participation of the
benzodiazepine binding site. The potentiating action of 30 mM
glabridin on the current evoked by 3 mM GABA on α1β2γ2 re-
ceptors was not signiﬁcantly altered by 1 mM ﬂumazenil, an in-
dication that glabridin did not act at the benzodiazepine bindingsite (Fig. 3).
Next, we evaluated the relevance of β subunits for glabridin-
induced potentiation. The anesthetics propofol and etomidate are
among the strongest GABA potentiators known to interact with
the β subunit [5]. We therefore asked whether the asparagine at
position 265 or the methionine at position 286, which are known
to be involved in the interaction with propofol and etomidate
[13,14], could also be involved in the potentiating mechanism of
glabridin. We evaluated the effect of increasing concentrations of
glabridin on β2(N265M) and β2(M286W) mutants. In comparison
to the α1β2(WT)γ2 mutant, the α1β2(N265M)γ2 mutant pre-
sented a marked decrease in its sensitivity towards glabridin as
well as in the maximal effect achieved by this compound. Neither
a potentiating effect nor any shift in the dose-response curve for
GABA could be observed in the β2(M286W) mutant (Fig. 4a, b).
The current induced by 3 mM GABA on the β2(N265M) mutant was
not signiﬁcantly potentiated by 30 mM glabridin; however, glab-
ridin induced a small GABA-EC50 shift from 141.97737.50 mM to
40.5774.29 mM (Fig. 4c and Table 2).4. Discussion
GABA is the major inhibitory neurotransmitter in the central
nervous system (CNS). GABAA receptors are a target for the ma-
jority of clinically relevant anesthetics and for many neuroleptic,
anxiolytic and anticonvulsant drugs [2,4]. There are many plant-
Fig. 3. Action of ﬂumazenil on glabridin potentiation. The glabridin potentiation of
the current evoked by 3 mM GABA at the α1β2γ2 GABAA receptors was not sig-
niﬁcantly altered by 1 mM of the benzodiazepine inhibitor ﬂumazenil. Fig. 4. Modulation of mutant GABAA receptors by glabridin. (a) Dose-response
relationship for the effect of glabridin on GABA-induced currents on α1β2(M286W)
γ2 or α1β2(N265M)γ2 receptors compared to the α1β1γ2 subtype (n of 3–4 oocytes).
(b) Co-application of glabridin (30 mM) with various concentrations of GABA did not
lead to a shift of the dose response curve for GABA on the α1β2(M286W)γ2 subtype
(n of 4 oocytes). (c) Co-application of glabridin (30 mM) leads to a shift in the dose-
response curve of GABA on α1β2(N265M)γ2 receptors (n of 3 oocytes).
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the CNS level. These are able to induce sedative and anxiolytic
effects [6]. We evaluated ﬂavonoids contained in Glycyrrhiza spec.
and found that the isoﬂavonoid glabridin was the only potentiator
of the tested substances. However, glabrol, a suggested ligand for
the benzodiazepine site of GABAA receptors [8], could not be tested
due to its limited availability. Furthermore, previous studies on
dorsal raphe neurons indicated that the glabridin potentiates
GABA-induced currents [10]. However, until now, there have been
no studies about the effect of glabridin on recombinant GABAA
receptors. We demonstrated that glabridin has a strong po-
tentiating effect on heterologously expressed GABAA receptors. In
α1β2γ2 receptors, 30 mM glabridin reduced the EC50 for GABA 12-fold, with an EC50 of 6 mM for the potentiation effect. This is
somewhat higher than the EC50 of 0.7 mM described for the highly
effective modulation site in dorsal raphe neurons; however, here,
the exact subunit composition of the native GABAA receptor is
unknown.
By using mutated receptor subunits and pharmacological tools,
we demonstrated that glabridin potentiation is ﬂumazenil
K.M. Hoffmann et al. / Biochemistry and Biophysics Reports 6 (2016) 197–202202insensitive and uses a mechanism that is similar to that used by
general anesthetics, such as etomidate, loreclezole, pentobarbital
and propofol, involving the amino acids N265 and M286, which
are located in the second and the third transmembrane domain on
the ß-subunit of GABAA receptors [5,14]. The β2(M286W) muta-
tion completely abolishes both direct activation and potentiation
of glabridin. In addition, the β2(N265M) mutant nearly abolished
glabridin potentiation. Glabridin shows a weak preference for re-
ceptors containing the β2 or β3 subunit, and the EC50 of glabridin
potentiation is higher in β3-containing receptors. This is similar to
the anesthetics etomidate and loreclezole, which also potentiate
α1β3γ2 and α1β2γ2 subunit combinations better than α1β1γ2
[15]. In terms of potency, glabridin can be compared with propofol,
for which EC50 values in the range of 2 mM were reported for the
potentiation of α1β2γ2 receptors [16].
Flavonoids have various pharmacological effects that are con-
gruent with their roles as modulators of GABAA receptors. They
often act on the benzodiazepine binding site, but other mechan-
isms have also been proposed [6]. Glabridin is a major ﬂavonoid in
G. glabra, and high contents in the dry weight of roots of up to
0.35% were reported [17]. However, the hypnotic effect of G. glabra
extracts is ﬂumazenil sensitive and is probably mediated by a
mechanism involving the benzodiazepine binding site. It was
suggested to be mainly caused by the ﬂavonoid glabrol [8].
Nevertheless, glabridin could contribute to the hypnotic effect, as
it is able to cross the blood-brain-barrier [18]. In contrast to po-
tentiators acting on the benzodiazepine site, higher doses of
glabridin directly activate GABAA receptors through a different,
propofol-like mechanism that could therefore induce sleep like
higher doses of barbiturates [19]. Interestingly, Glycyrrhiza extracts
also act on the 5HT3A receptor [20], another member of the family
of ligand-gated ion channels that is a target for anti-emetic drugs.
Here, glabridin is a blocker of the channel, although with a lower
potency compared to GABAA receptors.
Our results suggest that glabridin deserves further study as a
possible sedative or hypnotic agent.Acknowledgements
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